https://scholars.lib.ntu.edu.tw/handle/123456789/470766
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Yang P.-W. | en_US |
dc.contributor.author | PEI-MING HUANG | en_US |
dc.contributor.author | Yong L.-S. | en_US |
dc.contributor.author | Chang Y.-H. | en_US |
dc.contributor.author | Wu C.-W. | en_US |
dc.contributor.author | KUO-TAI HUA | en_US |
dc.contributor.author | MIN-SHU HSIEH | en_US |
dc.contributor.author | JANG-MING LEE | en_US |
dc.creator | Yang P.-W.;Huang P.-M.;Yong L.-S.;Chang Y.-H.;Wu C.-W.;Hua K.-T.;Min-Shu Hsieh;Lee J.-M. | - |
dc.date.accessioned | 2020-03-05T08:04:00Z | - |
dc.date.available | 2020-03-05T08:04:00Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048519452&doi=10.1245%2fs10434-018-6532-4&partnerID=40&md5=cc10cbac8b85eb6c8d2c3dab6cd108b8 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/470766 | - |
dc.description.abstract | Background: No effective targeted therapy exists for esophageal squamous cell carcinoma (ESCC), the major cell type of esophageal cancer. The pleiotropic cytokine interleukin (IL)-6 is associated with adverse prognosis of some cancers, and the open reading frame of IL-6 contains an miR-608 microRNA-targeted site. We investigated the correlation of circulating IL-6 levels with prognosis and with the mir608:rs4919510 genetic polymorphism in ESCC. Methods: A total of 213 patients with primary ESCC were enrolled. Plasma IL-6 levels of ESCC patients were analyzed by enzyme-linked immunosorbent assay (ELISA). The patients’ genotypes of mir608:rs4919510 were analyzed using the MassARRAY system, and functional assays were performed by transient overexpression in cells. The cytotoxicity of IL-6 signaling blockers in ESCC cells was analyzed by MTT assay. Results: We found that plasma IL-6 levels significantly correlated with overall survival (p = 0.019), disease recurrence (p = 0.003), and postoperative complications (p =0.002). Patients with the GG genotype of mir608:rs4919510 had a 4.56-fold increased risk of high expression of IL-6 compared with patients with the CC genotype (odds ratio 4.56, 95% confidence interval 1.87–11.09; p =0.001). Transient overexpression of the miR-608?C (miR-608_C) and G variants (miR-608_G) in cancer cells revealed that the miR-608_G variant was less efficient in regulating the expression of IL-6 compared with miR-608_C. Finally, the IL-6 signaling blocker ruxolitinib exhibited effective cytotoxicity in ESCC cells. Conclusions: The results of this study provide a novel direction for a biomarker-based targeted therapy for ESCC. ? 2018, Society of Surgical Oncology. | - |
dc.publisher | Springer New York LLC | - |
dc.relation.ispartof | Annals of Surgical Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | interleukin 6; microRNA; microRNA 608; ruxolitinib; tofacitinib; unclassified drug; IL6 protein, human; interleukin 6; microRNA; MIRN608 microRNA, human; tumor marker; adult; aged; Article; cancer prognosis; cancer risk; clinical outcome; cytotoxicity; enzyme linked immunosorbent assay; esophageal squamous cell carcinoma; esophageal squamous cell carcinoma cell line; female; genetic polymorphism; genotype; human; human cell; major clinical study; male; MTT assay; overall survival; postoperative complication; recurrent disease; blood; esophagus resection; esophagus tumor; follow up; gene expression regulation; genetics; middle aged; pathology; prognosis; single nucleotide polymorphism; squamous cell carcinoma; survival rate; tumor cell culture; tumor recurrence; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genotype; Humans; Interleukin-6; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Postoperative Complications; Prognosis; Survival Rate; Tumor Cells, Cultured | - |
dc.title | Circulating Interleukin-6 is Associated with Prognosis and Genetic Polymorphisms of MIR608 in Patients with Esophageal Squamous Cell Carcinoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1245/s10434-018-6532-4 | - |
dc.identifier.pmid | 29948421 | - |
dc.identifier.scopus | 2-s2.0-85048519452 | - |
dc.relation.pages | 2449-2456 | - |
dc.relation.journalvolume | 25 | - |
dc.relation.journalissue | 8 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Toxicology | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Pathology-NTUH | - |
crisitem.author.dept | Pathology-NTUCC | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.orcid | 0000-0001-5493-7673 | - |
crisitem.author.orcid | 0000-0002-8468-4977 | - |
crisitem.author.orcid | 0000-0002-0594-3732 | - |
crisitem.author.orcid | 0000-0001-9727-227X | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。